Aminocaproic Acid

證據等級: L5

預測適應症: 1 個

Aminocaproic Acid: From Hemorrhage Control to Severe Nonproliferative Diabetic Retinopathy

One-Sentence Summary

Aminocaproic acid is a synthetic lysine analogue antifibrinolytic agent, clinically used to control excessive bleeding by inhibiting the fibrinolytic system. The TxGNN model predicts it may be effective for Severe Nonproliferative Diabetic Retinopathy, however no clinical trials and no published literature currently support this direction.

Quick Overview

Item	Content
Original Indication	Antifibrinolytic agent (hemorrhage control, excessive fibrinolysis)
Predicted New Indication	Severe Nonproliferative Diabetic Retinopathy
TxGNN Prediction Score	99.27%
Evidence Level	L5
Saudi Arabia Market Status	Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Aminocaproic acid is a synthetic lysine analogue that competitively inhibits plasminogen binding to fibrin, thereby suppressing the fibrinolytic system. It is primarily used clinically to manage excessive bleeding in settings such as post-surgical hemorrhage and hyperfibrinolytic states. Formal MOA data is not yet available in the current dataset, but this antifibrinolytic mechanism is well-established in pharmacological literature and provides the basis for evaluating the repurposing hypothesis.

In diabetic retinopathy, the coagulation–fibrinolysis balance is disrupted: elevated PAI-1 (plasminogen activator inhibitor-1) and a tPA/PAI-1 imbalance have been associated with retinal microvascular damage. In theory, an antifibrinolytic agent might reduce microhemorrhage by stabilising clot formation at sites of microvascular injury.

However, the pathological core of severe nonproliferative diabetic retinopathy (severe NPDR) is microvascular occlusion and retinal ischaemia — not excessive fibrinolysis. Further suppression of fibrinolysis risks aggravating microvascular thrombosis and accelerating disease progression. The mechanistic link is therefore weak and directionally questionable, which is consistent with the L5 evidence classification and the Hold recommendation.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: This prediction rests entirely on model output with no supporting clinical trials or published literature. More critically, the proposed mechanism — antifibrinolysis — may be directionally harmful in severe NPDR, where the underlying pathology is microvascular occlusion rather than pathological fibrinolysis.

To proceed, the following is needed:

Formal MOA and safety data (key warnings, contraindications, DDIs) to be retrieved from DrugBank and the package insert
Preclinical data in animal models of diabetic retinopathy to assess ocular bioavailability and safety
A clear mechanistic hypothesis explaining why antifibrinolytic activity would be beneficial — rather than harmful — in the context of retinal ischaemia
At minimum one exploratory observational study or mechanistic study (to reach L4) before any clinical consideration
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.